TRACON Pharmaceuticals (NASDAQ:TCON) Earns Hold Rating from Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research report issued on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Price Performance

Shares of NASDAQ TCON opened at $0.03 on Friday. TRACON Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $14.75. The company’s 50-day moving average is $0.05 and its 200 day moving average is $0.37. The stock has a market capitalization of $109,802.00, a P/E ratio of 0.01 and a beta of 1.37.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.